Skip to main content

Michael D Deel, MD

Assistant Professor of Pediatrics
Member of the Duke Cancer Institute
Member of the Duke Cancer Institute
Campus mail: Duke University Medical Center, Box 102382, Durham, NC 27710
Phone: (919) 681-6173
Email address: michael.deel@duke.edu

Dr. Deel is a clinician scientist in Pediatric Hematology/Oncology. In addition to caring for pediatric patients with hematologic disorders or malignancy, his research focuses on finding novel ways to target fusion-positive pediatric sarcomas. His current work focuses on understanding the gene regulation and molecular pathways responsible for alveolar rhabdomyosarcoma, which is among the most difficult to cure pediatric cancers. Alveolar rhabdomyosarcoma is driven by chromosomal translocations t(2;13) or t(1;13) that result in oncogenic transcription factors encoding for PAX3/7-FOXO1 fusion proteins. The PAX3/7-FOXO1 oncogenes are currently not viable therapeutic targets. Using a variety of cell culture and murine models, Dr. Deel is investigating genes and pathways that regulate or coordinate PAX3/7-FOXO1-mediated tumorigenesis.

Education and Training

  • Advanced Pediatric/Oncology Research Training, Pediatrics/Duke University School Of Medicine, Duke University School of Medicine, 2016 - 2017
  • Pediatric Hematology/Oncology Fellowship, Pediatrics/Duke University School Of Medicine, Duke University School of Medicine, 2013 - 2016
  • Internshipand Residency, Pediatrics/University Of Louisville, University of Louisville, 2010 - 2013
  • M.D., Marshall University, Joan C. Edwards School of Medicine, 2010

Publications

Deel, Michael, Tooba Rashid, Breanne Burgess, Crystal Chiu, Krislyn Cardoza, Sebnem Egriboyun, and Corinne Linardic. “YAP1 AND WWTR1 REGULATE PAX3-FOXO1 TRANSCRIPTIONAL PROGRAMMING IN FUSION-POSITIVE RHABDOMYOSARCOMA.” In Pediatric Blood & Cancer, 67:S126–S126. WILEY, 2020.

Scholars@Duke

Lin, Yi-Tzu, Michael D. Deel, and Corinne M. Linardic. “RASSF4 is required for skeletal muscle differentiation.” Cell Biol Int 44, no. 2 (February 2020): 381–90. https://doi.org/10.1002/cbin.11238.

Full Text

Burgess, Breanne A., Katherine K. Slemmons, Corinne M. Linardic, and Michael D. Deel. “Abstract 3670: Transcriptional co-activators TAZ/YAP are novel regulators of PAX3-FOXO1 transcriptional programing and fusion-positive rhabdomyosarcoma cancer cell stemness.” In Tumor Biology. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.am2019-3670.

Full Text

Deel, Michael D., Katherine K. Slemmons, Ashley R. Hinson, Katia C. Genadry, Breanne A. Burgess, Lisa E. S. Crose, Nina Kuprasertkul, Kristianne M. Oristian, Rex C. Bentley, and Corinne M. Linardic. “The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.” Clin Cancer Res 24, no. 11 (June 1, 2018): 2616–30. https://doi.org/10.1158/1078-0432.CCR-17-1207.

Full Text

Deel, Michael, Katherine Slemmons, Ashley Hinson, Lisa Crose, Nina Kupraserkul, Kristianne Oristian, Rex Bentley, and Corinne Linardic. “The Transcriptional Co-Activator TAZ is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.” In Pediatric Blood & Cancer, 64:S4–S4. WILEY, 2017.

Scholars@Duke

Deel, Michael, Katrina Slemmons, Rex Bentley, and Corinne Linardie. “INVESTIGATING THE ROLE OF THE TRANSCRIPTIONAL CO-ACTIVATOR TAZ IN ALVEOLAR RHABDOMYOSARCOMA.” In Pediatric Blood & Cancer, 63:S63–64. WILEY-BLACKWELL, 2016.

Scholars@Duke

Deel, Michael D., Jenny J. Li, Lisa E. S. Crose, and Corinne M. Linardic. “A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.” Front Oncol 5 (2015): 190. https://doi.org/10.3389/fonc.2015.00190.

Full Text

Deel, Michael, Roger McLendon, Oren Becher, Matthias Karajannis, Jeffrey Wisoff, Carrie Muh, Kristin Schroeder, and Sri Gururangan. “HER2 AMPLIFICATION OR POLYSOMY CHROMOSOME 17 (PCH17) IN BRAINSTEM PILOCYTIC ASTROCYTOMA (PA).” In Neuro Oncology, 16:65–65. OXFORD UNIV PRESS INC, 2014.

Scholars@Duke

Deel, Michael D., Maiying Kong, Keith P. Cross, and Salvatore J. Bertolone. “Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children.” Pediatr Blood Cancer 60, no. 12 (December 2013): 1967–74. https://doi.org/10.1002/pbc.24628.

Full Text